on Innovative Molecules GmbH
Innovative Molecules Advances with New EBV Antiviral Program
Innovative Molecules GmbH ("IM"), a biopharmaceutical company in Munich, has announced the expansion of its virology pipeline. The company is introducing a novel Epstein-Barr Virus (EBV) antiviral program, featuring potent polymerase inhibitors. This program is set to enter Phase 1 by 2027.
EBV is linked to serious diseases such as lymphoproliferative disorders and autoimmune conditions, yet there are few targeted antiviral treatments available. IM's new initiative highlights its commitment to addressing these unmet medical needs with specialized antiviral therapies.
Florian Vogel, CEO of Innovative Molecules, emphasized the growing importance of EBV as a therapeutic area and expressed the company's dedication to advancing innovative treatments for viral diseases. This program supports IM's strategy to develop a robust portfolio targeting high-value medical needs.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Innovative Molecules GmbH news